489 related articles for article (PubMed ID: 33202035)
1. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
Potts MA; McDonald JA; Sutherland KD; Herold MJ
Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
[TBL] [Abstract][Full Text] [Related]
3. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
4. Development and application of CRISPR/Cas9 technologies in genomic editing.
Zhang C; Quan R; Wang J
Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
[TBL] [Abstract][Full Text] [Related]
5. Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery.
Ahmad G; Amiji M
Drug Discov Today; 2018 Mar; 23(3):519-533. PubMed ID: 29326075
[TBL] [Abstract][Full Text] [Related]
6. Advance genome editing technologies in the treatment of human diseases: CRISPR therapy (Review).
Alagoz M; Kherad N
Int J Mol Med; 2020 Aug; 46(2):521-534. PubMed ID: 32467995
[TBL] [Abstract][Full Text] [Related]
7. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
Wu HY; Cao CY
Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
[TBL] [Abstract][Full Text] [Related]
8. Engineering T Cells Using CRISPR/Cas9 for Cancer Therapy.
Zhang X; Cheng C; Sun W; Wang H
Methods Mol Biol; 2020; 2115():419-433. PubMed ID: 32006414
[TBL] [Abstract][Full Text] [Related]
9. Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9.
Afolabi LO; Adeshakin AO; Sani MM; Bi J; Wan X
Immunology; 2019 Oct; 158(2):63-69. PubMed ID: 31315144
[TBL] [Abstract][Full Text] [Related]
10. Tumor immunology CRISPR screening: present, past, and future.
Dong MB; Tang K; Zhou X; Zhou JJ; Chen S
Trends Cancer; 2022 Mar; 8(3):210-225. PubMed ID: 34920978
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges.
Cheng X; Fan S; Wen C; Du X
Brief Funct Genomics; 2020 May; 19(3):209-214. PubMed ID: 32052006
[TBL] [Abstract][Full Text] [Related]
12. CRISPR Cas System: An efficient tool for cancer modelling.
Akhtar M; Jamal T; Khan M; Khan SR; Haider S; Jalil F
J Pak Med Assoc; 2021 Feb; 71(2(B)):718-724. PubMed ID: 33941966
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-cas System as a Genome Engineering Platform: Applications in Biomedicine and Biotechnology.
Hashemi A
Curr Gene Ther; 2018; 18(2):115-124. PubMed ID: 29473500
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 System and its Research Progress in Gene Therapy.
Liu W; Yang C; Liu Y; Jiang G
Anticancer Agents Med Chem; 2019; 19(16):1912-1919. PubMed ID: 31633477
[TBL] [Abstract][Full Text] [Related]
15. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Cas9: from Genome Editing to Cancer Research.
Chen S; Sun H; Miao K; Deng CX
Int J Biol Sci; 2016; 12(12):1427-1436. PubMed ID: 27994508
[TBL] [Abstract][Full Text] [Related]
17. [CRISPR-Cas system as molecular scissors for gene therapy].
Heinz GA; Mashreghi MF
Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
[TBL] [Abstract][Full Text] [Related]
18. CRISPR Diagnosis and Therapeutics with Single Base Pair Precision.
Lee SH; Park YH; Jin YB; Kim SU; Hur JK
Trends Mol Med; 2020 Mar; 26(3):337-350. PubMed ID: 31791730
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
[TBL] [Abstract][Full Text] [Related]
20. Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review.
Ebrahimi V; Hashemi A
Gene; 2020 Aug; 753():144813. PubMed ID: 32470504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]